Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a SAD and Food Effect Study of TS-134
NCT03746067Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing TS-134 with Placebo (2 arms). Primary endpoints: Incidence and severity of Adverse Events, TS-134 Plasma Pharmacokinetic Profile - Cmax and 5 more. Started Aug 2015; status: completed.
02
Drugs
TS-134
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03746067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03746067.